Clinical Trial

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination to evaluate safety and immunogenicity in healthy population aged 18 years old and above.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05911048
Lead Sponsor WestVac Biopharma Co., Ltd.
Conditions COVID-19
Enrollment 3,100 participants
Start Date 2024-12-30
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-25